Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
The primary aim of this study was to examine the effect of severe renal impairment (SRI) on the pharmacokinetics of lemborexant, a dual orexin receptor antagonist indicated for the treatment of insomnia. A phase 1 multicenter, single‐dose, open‐label, parallel‐group study was conducted in subjects with SRI not requiring dialysis (estimated glomerul...
Alternative Titles
Full title
Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e985b0e98d5745aa8710e3cb42b80741
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e985b0e98d5745aa8710e3cb42b80741
Other Identifiers
ISSN
2052-1707
E-ISSN
2052-1707
DOI
10.1002/prp2.734
